India Immune-Oncology Drugs Market Detailed In New Research Report 2021-2028 | Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca

The India immune-oncology drugs market include increased cancer testing, new product releases, sales and marketing approvals, and an increase in the number of development programs. Various organizations are working to introduce new medicines that will help India's immune-oncology drug market achieve a decent share of the market. Hervycta (Trastuzumab), a biosimilar to Roche's Herceptin, was introduced in India by Dr. Reddy's Laboratories Ltd. in July 2018. It is used to treat cancers that are HER2-positive. Furthermore, Biocon unveiled Krabeva, a biosimilar Bevacizumab, in India in November 2017 for the treatment of patients with metastatic colorectal cancer and other forms of breast, prostate, cervical, ovarian, and brain cancers.

Request Sample Report + Related Graphs & Charts @:
https://www.coherentmarketinsights.com/insight/request-sample/2631

Key Players in This Report Include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories Ltd., Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.

Furthermore, several firms are working to obtain distribution and marketing licenses from Indian regulatory bodies in order to import their medicines, which may boost the growth of the India immuno-oncology drugs market. The Drug Controller General of India (DCGI) granted AstraZeneca Pharma India Limited Import & Launch Permission for Durvalumab (Imfinzi) in India in June 2018. Manufacturers in the India immune-oncology drugs market are focused on strategic partnership in order to gain substantial market share.

Dr. Reddy's Laboratories Ltd. extended its strategic partnership with Amgen in September 2016 to sell and supply Amgen's three oncology and osteoporosis medicines (XGEVA (denosumab), Vectibix (panitumuma), and Prolia (denosumab) in India. To advance their own experiments on new drugs, Bristol-Myers Squibb stresses partnerships with other biopharmaceutical and pharmacy firms.

In 2017, AbbVie and Bristol-Myers Squibb partnered on Opdivo and ABBV-399 studies. Bristol-Myers Squibb and Seattle Genetics teamed up to study Adcetris and Opdivo, two drugs used to cure relapsed or refractory Hodgkin lymphoma.

Request for customization in Report @ https://www.coherentmarketinsights.com/insight/request-customization/2631

AstraZeneca Plc. is working to raise awareness of Indians in order to expand its market share in the country. In February 2018, AstraZeneca Pharma India Limited and the Indian Cancer Society launched Cancer Screening for Women, a national cancer awareness campaign. This service provided free, advanced cancer screening to women from low-income families around the world.

Key Takeaways

Due to increased research and development and demand for genetic and repertoire sequencing-based research, the India immune-oncology drugs market is expected to grow at a CAGR of 13.1 percent over the forecast period (2021–2028).

Due to the growing number of product releases, the Monoclonal Antibodies market is projected to have the largest sales share in 2026. Hetero Group (Hetero), an Indian generics company, unveiled its biosimilar ‘Rituximab' under the brand name of MABALL in India in August 2018. Rituximab is a single-dose vial with two strengths – 100mg/10ml and 500mg/50ml – that is prescribed as the first-line therapy for Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukaemia (CLL).

Key companies contributing in the India immune-oncology drugs market are Dr. Reddy's Laboratories Ltd., Merck & Co., Inc., AstraZeneca plc., Intas Pharmaceuticals Ltd., Amgen, Inc., Biocon Limited, Hetero Drugs Limited., F. Hoffmann-La Roche AG, Reliance Life Sciences, Mylan N.V., BIOCAD-Biotechnology Company, and Bristol - Myers Squibb.

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/2631

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.